We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-5.01%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$7.91B
AUM Growth
-$1.41B
Cap. Flow
-$1B
Cap. Flow %
-12.68%
Top 10 Hldgs %
40.65%
Holding
174
New
35
Increased
19
Reduced
37
Closed
35

Top Buys

Rank Stock Value
1
LABP
Landos Biopharma, Inc. Common Stock
LABP
+$194M
2
BBIO icon
BridgeBio Pharma
BBIO
+$68.7M
3
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$68.4M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$62.1M
5
SWTX
SpringWorks Therapeutics
SWTX
+$52.6M

Top Sells

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$116M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$100M
3
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$90.4M
4
NVTA
Invitae Corporation
NVTA
+$87.4M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$87.3M

Sector Composition

Rank Sector Weight
1 Healthcare 80.08%
2 Financials 0.47%
3 Industrials 0.2%
4 Consumer Discretionary 0.02%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYNB
101
PUT
Kyntra Bio
KYNB
$28.1M
$6.94M 0.09%
+8,000
New +$8.52M
TCRR
102
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$6.92M 0.09%
313,300
-86,700
-22% -$2.36M
TARA icon
103
Protara Therapeutics
TARA
$215M
$6.64M 0.08%
421,642
-186,902
-31% -$3.47M
DRIO icon
104
DarioHealth
DRIO
$51.3M
$6.31M 0.08%
+16,393
New +$7.39M
AMWL icon
105
American Well
AMWL
$184M
$6.17M 0.08%
17,750
-8,500
-32% -$4.61M
SNDX icon
106
Syndax Pharmaceuticals
SNDX
$1.7B
$6.04M 0.08%
270,000
-30,000
-10% -$678K
VINC
107
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$5.79M 0.07%
15,000
– –
ATXS
108
DELISTED
Astria Therapeutics
ATXS
$5.59M 0.07%
+322,259
New +$5.82M
TNGX icon
109
Tango Therapeutics
TNGX
$4.22B
$5.56M 0.07%
500,000
– –
PHR icon
110
Phreesia
PHR
$681M
$5.21M 0.07%
100,000
– –
OBIO icon
111
Orchestra BioMed
OBIO
$233M
$5.04M 0.06%
450,000
– –
LGV.U
112
DELISTED
Longview Acquisition Corp. II Units, each consisting of one share of Class A Common Stock and one-fifth of one redeemable Warrant
LGV.U
$5.02M 0.06%
+500,000
New +$5.02M
CHFW.U
113
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$4.88M 0.06%
500,000
– –
DFHTU
114
DELISTED
Deerfield Healthcare Technology Acquisitions Corp. Unit
DFHTU
$3.93M 0.05%
300,000
– –
TXMD icon
115
TherapeuticsMD
TXMD
$24M
$3.69M 0.05%
+55,000
New +$4.31M
MRUS
116
DELISTED
Merus
MRUS
$3.65M 0.05%
+175,000
New +$4.04M
VRAY
117
DELISTED
ViewRay, Inc.
VRAY
$3.27M 0.04%
751,748
-1,700,000
-69% -$8.26M
TLIS
118
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$3.21M 0.04%
+16,667
New +$4.16M
SNCE
119
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$3.04M 0.04%
15,000
– –
SGTX
120
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$2.79M 0.04%
9,615
– –
RGNX icon
121
Regenxbio
RGNX
$617M
$2.36M 0.03%
+69,283
New +$2.95M
GRTX
122
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$2.25M 0.03%
254,664
-70,336
-22% -$772K
MOTS
123
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$2.07M 0.03%
6,002
-8,033
-57% -$3.5M
PLXP
124
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$2.01M 0.03%
+222,180
New +$1.62M
WGS icon
125
GeneDx Holdings
WGS
$1.91B
$1.89M 0.02%
+3,848
New +$2M
3 4
5
6 7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Perceptive Advisors held 174 positions worth $7.91B, down 15% from $9.32B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Perceptive Advisors withdrew a net $1B in Q1 2021, closing 35 positions and reducing 37 holdings. Its most notable exit was Novavax, an estimated $116M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in Landos Biopharma, Inc. Common Stock worth $141M.

  • Perceptive Advisors's largest Q1 2021 buy was Landos Biopharma, Inc. Common Stock: 1,486,992 shares worth $141M.
  • Perceptive Advisors added most to BridgeBio Pharma in Q1 2021, an estimated $68.7M increase.
  • Perceptive Advisors's biggest Q1 2021 reduction was Neurocrine Biosciences, cutting an estimated $100M.
  • Perceptive Advisors fully exited Novavax in Q1 2021, selling an estimated $116M.
  • Perceptive Advisors's ten largest holdings make up 41% of its $7.91B portfolio in Q1 2021.
  • Perceptive Advisors opened 35 new positions and closed 35 in Q1 2021.
  • Perceptive Advisors's portfolio value fell 15% quarter-over-quarter to $7.91B.

Based on Perceptive Advisors's 13F filing for Q1 2021, filed 17 May 2021.